74 results about "Developmental disorder" patented technology

Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.

This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.

An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.

In one embodiment, a method for detecting autism in a natural language environment using a microphone, sound recorder, and a computer programmed with software for the specialized purpose of processing recordings captured by the microphone and sound recorder combination, the computer programmed to execute the method, includes segmenting an audio signal captured by the microphone and sound recorder combination using the computer programmed for the specialized purpose into a plurality recording segments. The method further includes determining which of the plurality of recording segments correspond to a key child. The method further includes determining which of the plurality of recording segments that correspond to the key child are classified as key child recordings. Additionally, the method includes extracting phone-based features of the key child recordings; comparing the phone-based features of the key child recordings to known phone-based features for children; and determining a likelihood of autism based on the comparing.

In one embodiment, a method for detecting autism in a natural language environment using a microphone, sound recorder, and a computer programmed with software for the specialized purpose of processing recordings captured by the microphone and sound recorder combination, the computer programmed to execute the method, includes segmenting an audio signal captured by the microphone and sound recorder combination using the computer programmed for the specialized purpose into a plurality recording segments. The method further includes determining which of the plurality of recording segments correspond to a key child. The method further includes determining which of the plurality of recording segments that correspond to the key child are classified as key child recordings. Additionally, the method includes extracting phone-based features of the key child recordings; comparing the phone-based features of the key child recordings to known phone-based features for children; and determining a likelihood of autism based on the comparing.

The methods and apparatus disclosed herein can diagnose or identify a subject as at risk of having one or more developmental disorders with fewer questions, decreased amounts of time, and determine a plurality of developmental disorders, and provide clinically acceptable sensitivity and specificity in a clinical environment. The methods and apparatus disclosed herein can be configured to diagnose or determine the subject as at risk of a developmental disorder among a plurality of developmental disorders, and decreasing the number of questions presented can be particularly helpful where a subject presents with a plurality of possible developmental disorders. A processor can be configured with instructions to identify a most predictive next question, such that a person can be diagnosed or identified as at risk with fewer questions.

The present invention provides a composition improving memory and a preparation method thereof. The composition mainly consists of the following components: a semen ziziphi spinosae extract, phosphatidylserine and DHA (docosahexenoic acid). The composition can greatly reduce the required amounts of phosphatidylserine and DHA to play the same functions, and has efficacies of preventing and curing brain developmental disorders of infants and pregnant women, adolescent mental deterioration, and premature senile cranial nerve degeneration.

A program module is configured with sub-modules for child development assessment, presentation of progress charts and development of individualized treatment plans. An assessment sub-module includes assessment tools for behavioral educators of children with developmental disorders to identify mastered and non-mastered skills of a subject child. A treatment plan sub-module is configured to permit the behavioral educator to determine a set of lessons from a curriculum, which lessons define an individualized, Applied Behavior Analysis (ABA)-based program of instruction based on the needs of a subject child as identified by the assessment tools. A progress chart sub-module is configured to permit monitoring of the subject child's progress as the subject child progresses through the lessons of the individualized program under the guidance of one or more instructors.

This invention relates to a method of treating or preventing neuro-degenerative disorders and neuro-developmental disorders by altering the ratio of the amount of full-length TrkB polypeptide to the amount of truncated TrkB polypeptides in a neuron or by altering the ratio of the amount of full-length TrkC polypeptide to the amount of truncated TrkC polypeptides in a neuron.

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula

wherein each symbol is as defined in the present specification, or a salt thereof.

Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.

The invention relates to application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases. The preservation number of the lactobacillus reuteri is CGMCC (China General Microbiological Culture Collection Center) No. 21577. The lactobacillus reuteri can improve the composition of intestinal flora of patients with developmental disorder diseases such as the Prallard-Willard syndrome and the autism, and improve the disorder of the intestinal flora. The bacteria can prevent obesity or promote weight loss caused by diet, can improve brain development of patients with developmental disorder diseases such as the Prallard-Willie syndrome and autism, can improve social contact disorders and communication disorders of the patients, and can improve fine exercise ability of the patients.